Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript

What happened: Mirum Pharmaceuticals, Inc. published a slide deck in conjunction with an event discussing Phase 3 EXPAND study results for Maralixibat in cholestatic pruritus, including biliary atresia. Why it matters: The content does not state analyst reaction, market move, or guidance change, so no significance is expressed in the supplied material. Total characters: about 330.

Mirum Pharmaceuticals, Inc. published a slide deck in conjunction with an event discussing Phase 3 EXPAND study results for Maralixibat in cholestatic pruritus, including biliary atresia.

The content does not state analyst reaction, market move, or guidance change, so no significance is expressed in the supplied material. Total characters: about 330.